Cargando…
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas
Meningiomas are the most common primary intracranial adult tumor. All Neurofibromatosis 2 (NF2)-associated meningiomas and ~60% of sporadic meningiomas show loss of NF2 tumor suppressor protein. There are no effective medical therapies for progressive and recurrent meningiomas. Our previous work dem...
Autores principales: | Beauchamp, Roberta L., James, Marianne F., DeSouza, Patrick A., Wagh, Vilas, Zhao, Wen-Ning, Jordan, Justin T., Stemmer-Rachamimov, Anat, Plotkin, Scott R., Gusella, James F., Haggarty, Stephen J., Ramesh, Vijaya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627286/ https://www.ncbi.nlm.nih.gov/pubmed/26219339 |
Ejemplares similares
-
Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas
por: Shen, Yiping, et al.
Publicado: (2009) -
mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition
por: Beauchamp, Roberta L., et al.
Publicado: (2020) -
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2
por: Jordan, Justin T, et al.
Publicado: (2023) -
Mediator Subunit Med28 Is Essential for Mouse Peri-Implantation Development and Pluripotency
por: Li, Lin, et al.
Publicado: (2015) -
Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients
por: Nunes, Fabio P., et al.
Publicado: (2013)